Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory DLBCL not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma, after two or more systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
A fixed-duration bispecific regimen added an option after multiple prior therapies.
What research teams should watch
Verify lymphoma subtype and plan pretreatment, step-up infusions and cytokine release syndrome surveillance.
PRIMARY RECORDS